Treatment of Hypertension in a 72-Year-Old Female
For a 72-year-old female with hypertension, initiate treatment with a low-dose ACE inhibitor or ARB as first-line therapy, titrate to full dose if needed, then add a thiazide-like diuretic or dihydropyridine calcium channel blocker as second-line, targeting a blood pressure of <140/90 mmHg (or <130/80 mmHg if she is robust and tolerates treatment well). 1
Initial Assessment and Risk Stratification
Before starting treatment, confirm the diagnosis with home blood pressure monitoring (target <135/85 mmHg) or 24-hour ambulatory monitoring (target <130/80 mmHg) 1. At 72 years old, she falls into the high-risk category and should begin pharmacological treatment immediately if BP ≥140/90 mmHg, alongside lifestyle interventions 1.
Critical assessment point: Evaluate her frailty status using validated clinical tests 2. This is the single most important factor that will determine your BP target and treatment intensity. The 2020 ISH guidelines explicitly state to "individualize for elderly based on frailty" 1, and the 2024 ESC guidelines provide the most recent guidance distinguishing robust from frail elderly patients 2.
Blood Pressure Targets Based on Frailty
If She is Robust (Not Frail)
- Target: <130/80 mmHg 2
- The 2024 ESC guidelines (most recent) recommend this stricter target for robust elderly patients under 85 years 2
- The 2025 AHA/ACC guidelines support intensive BP lowering in community-dwelling older adults who tolerate treatment well 3
If She is Frail or Has Multiple Comorbidities
- Target: <140/90 mmHg 1, 2
- Use the "as low as reasonably achievable" (ALARA) principle if she cannot tolerate achieving lower targets 2
- Consider monotherapy initially in frail patients 1
Pharmacological Treatment Algorithm
Step 1: First-Line Therapy
Start with low-dose ACE inhibitor or ARB 1
- This is the clear recommendation from the 2020 ISH guidelines for non-Black patients 1
- Examples: Lisinopril 5-10 mg daily, Losartan 25-50 mg daily
Step 2: Titration
Increase to full dose of ACE inhibitor/ARB 1
Step 3: Add Second Agent
Add either:
- Thiazide-like diuretic (preferred: chlorthalidone 12.5-25 mg daily or indapamide 1.25-2.5 mg daily), OR
- Dihydropyridine calcium channel blocker (amlodipine 5-10 mg daily) 1, 5
The evidence strongly supports thiazide diuretics and dihydropyridine CCBs as effective in elderly patients with isolated systolic hypertension, which is the predominant form at this age 5, 6, 7.
Step 4: Triple Therapy if Needed
Add the third drug class not yet used (CCB + thiazide + ACE/ARB) 1
Step 5: Resistant Hypertension
Add spironolactone 25 mg daily, or if not tolerated: amiloride, doxazosin, eplerenone, clonidine, or beta-blocker 1
Special Considerations for This Age Group
Orthostatic Hypotension Screening
Before starting or intensifying treatment, measure BP after 5 minutes of sitting/lying, then at 1 and 3 minutes after standing 2. If orthostatic hypotension is present, this may warrant a higher BP target (≥140/90 mmHg) 2.
Medication Simplification
- Use once-daily dosing whenever possible 1
- Consider single-pill combinations to improve adherence 1
- The 2020 ISH guidelines specifically recommend simplifying regimens in elderly patients 1
Monitoring Strategy
- Achieve target BP within 3 months 1
- Once controlled, follow up at least yearly for BP and cardiovascular risk factors 2
- Monitor for acute kidney injury, electrolyte disturbances, and falls 8
Important Caveats
Do not stop medications if BP drops below target without adverse effects 9. The JNC-8 explicitly states to continue therapy if lower BP is achieved without serious adverse effects 9.
Maintain treatment lifelong, even beyond age 85, if well tolerated 2. Multiple RCTs including HYVET and SPRINT have demonstrated mortality benefit in patients over 80 years 8.
Beta-blockers are NOT first-line in uncomplicated hypertension at this age 4, 10. Reserve them for compelling indications like heart failure, coronary artery disease, or atrial fibrillation 10.
Evidence Strength
The recommendations are based primarily on the 2020 ISH guidelines 1 and 2024 ESC guidelines 2, both published in high-impact journals (Hypertension and European Heart Journal). These are reinforced by the 2025 AHA/ACC guidelines 3 and supported by robust RCT evidence including HYVET and SPRINT trials showing mortality reduction in elderly patients 8, 7.